Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)

Veronica A Guerra, MD, Yan Yuanqing, PhD, Joanne Hsu, BS, Feng Wang, PhD, Mansour Alfayez, MD, Kiyomi Morita, MD, Xingzhi Song, PhD, Courtney D. DiNardo, MD MSc, Marina Y Konopleva, MD PhD, Gautam M. Borthakur, MD, Guillermo Montalban Bravo, MD, Jianhua Zhang, PhD, Latasha Little, BS, Curtis Gumbs, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Andrew Futreal, PhD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 458.

https://doi.org/10.1182/blood-2019-127498

Published: 2019

Journal Articles

Therapy Related Myeloid Neoplasms- Clinical, Pathologic and Genetic Characteristics - a Single Center Experience

Dina Sameh Soliman, MD MB, MMSc, Ahmed Al-Sabbagh, MD, Shehab Fareed Mohamed, MD, Susanna Jane Akiki, PhD, Halima El-Omri, MD, Firyal Ibrahim, MD, Mohamed A Yassin, MBBS, MSc, Prem Chandra, PhD

Blood (2019) 134 (Supplement_1): 5169.

https://doi.org/10.1182/blood-2019-124951

Published: 2019

Journal Articles

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Dina Sameh Soliman, MD MB, MMSc, Ahmad Al-Sabbagh, MD, Firyal Ibrahim, MD, Halima El-Omri, MD, Mohamed A Yassin, MBBS, MSc, Aliaa Amer, MD

Blood (2019) 134 (Supplement_1): 5113.

https://doi.org/10.1182/blood-2019-131683

Published: 2019

Journal Articles

Therapy-Related Myeloid Neoplasms Are Not Always Dismal If They Have Better Cytogenetic Profile and Longer Latency Period from Preceding Anti-Cancer Treatment

Junshik Hong, MD, Ji Yun Lee, MD, Ja Min Byun, MD, Dong-Yeop Shin, MDPhD, Youngil Koh, MD, Inho Kim, MD PhD, Sung-Soo Yoon, MD PhD

Blood (2017) 130 (Supplement 1): 1307.

https://doi.org/10.1182/blood.V130.Suppl_1.1307.1307

Published: 2017

Journal Articles

Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs

Kshama A. Doshi, PhD, Shivani Kapoor, MS, Ying Zou, MD PhD, Xiang Li, PhD, Mario Scarpa, MS, Nidal Muvarak, PhD, Pratik Nagaria, PhD, Olga Goloubeva, PhD MSc, Adriana E. Tron, PhD, Charles J. Bieberich, PhD, Feyruz V. Rassool, BSc, PhD, Maria R. Baer, MD

Blood (2017) 130 (Supplement 1): 1243.

https://doi.org/10.1182/blood.V130.Suppl_1.1243.1243

Published: 2017

Journal Articles

Impact of Bioflavonoid Exposure on DNA Damage Response and of Non-Homologous End Joining (NHEJ) Pathway Repair Proteins in Stem Cells

Anindita Ghosh, MBBS, MSc, Christine Richardson, PhD

Blood (2017) 130 (Supplement 1): 3796.

https://doi.org/10.1182/blood.V130.Suppl_1.3796.3796

Published: 2017

Journal Articles

Clinical and Molecular Characteristics of Therapy-Related Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 3993.

https://doi.org/10.1182/blood.V130.Suppl_1.3993.3993

Published: 2017

Journal Articles

Philadelphia (Ph) Chromosome ( BCR-ABL1 fusion) As a Recurrent Genetic Abnormality Among Therapy-Related Acute Leukemia

Ibrahim Aldoss, MD, Tracey Stiller, Joo Y. Song, MD, Monzr M al Malki, MD, Haris Ali, MD, Amandeep Salhotra, MD, Samer K Khaled, MD, Ahmed Aribi, MD, Popsie Gaytan, Joyce L. Murata-Collins, PhD, David S. Snyder, MD, Anthony S. Stein, MD, Margaret O'Donnell, MD, Ryotaro Nakamura, MD, Joycelynne M. Palmer, PhD, Stephen J. Forman, MD, Guido Marcucci, MD, Vinod Pullarkat, MD

Blood (2016) 128 (22): 3974.

https://doi.org/10.1182/blood.V128.22.3974.3974

Published: 2016

Journal Articles

Comparison of Two Rapid Predictive Methods for Therapeutic Targeting in Acute Myeloid Leukaemia Cells

Martin Grundy, PhD, Jones Thomas, BSc, Liban Elmi, B MDSci, Michael Hall, B MDSci, Nigel H Russell, MD, Monica Pallis, PhD

Blood (2016) 128 (22): 1704.

https://doi.org/10.1182/blood.V128.22.1704.1704

Published: 2016

Journal Articles

Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis

Croix Fossum, BS, Rhett P. Ketterling, MD, Lindsey E. Roeker, Ajoy L. Dias, MD, Michelle Elliott, MD, William J. Hogan, MBChB, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2015) 126 (23): 1401.

https://doi.org/10.1182/blood.V126.23.1401.1401

Published: 2015

Journal Articles

Emerging Risks of AML/MDS and Other Myeloid Neoplasms Following Chemotherapy for First Primary Malignancy, 2000-2012

Lindsay M Morton, PhD, Graca M. Dores, MD MPH, Meredith S Shiels, PhD, Martha S Linet, MD MPH, Jop C Teepen, Clara J.K. Lam, PhD, Margaret A. Tucker, MD, Rochelle E Curtis, MA

Blood (2015) 126 (23): 562.

https://doi.org/10.1182/blood.V126.23.562.562

Published: 2015

Journal Articles

Concomitant Acute Promyelocytic Leukemia and Chronic Lymphocytic Leukemia: Molecularly Two Distinct Diseases

Jingdong Su, MD, Hazem E. El-Osta, MD, Reinhold Munker, MD, Glenn M. Mills, MD, Srinivas S. Devarakonda, MD

Blood (2015) 126 (23): 4904.

https://doi.org/10.1182/blood.V126.23.4904.4904

Published: 2015

Journal Articles

Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?

Camille Bigenwald, Stephanie Harel, Florian Chevillon, Damien Roos-Weil, Olivier A. Bernard, PhD, Sandy Amorim, MD, Pauline Brice, MD, Ades Lionel, Anne Marie Nloga, Marie Sébert, MD, Thorsten Braun, MD PhD, Virginie Eclache, Catherine Thieblemont, MDPhD, Pierre Fenaux, MD PhD

Blood (2015) 126 (23): 2886.

https://doi.org/10.1182/blood.V126.23.2886.2886

Published: 2015

Journal Articles

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Daver Naval, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, Nitin Jain, MD, Gautam Borthakur, MD, Elias Jabbour, MD, Marina Konopleva, MD PhD, Jorge E. Cortes, MD, Adam Craig, MD PhD, Farhad Ravandi, MD

Blood (2014) 124 (21): 385.

https://doi.org/10.1182/blood.V124.21.385.385

Published: 2014

Journal Articles

Dinaciclib, a CDK Inhibitor, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition

David Alagpulinsa, BPham, Srinivas Ayyadevara, PhD, Shmuel Yaccoby, PhD, Robert shmookler Reis, DPhil

Blood (2014) 124 (21): 479.

https://doi.org/10.1182/blood.V124.21.479.479

Published: 2014

Journal Articles

Early Occurrence of Therapy-Related Acute Myeloid Leukemia (t-AML) with Monocytic Differentiation with Trisomy 8 Cytogenetic Abnormality after Radioactive Iodine (RAI) Treatment for Papillary Thyroid Cancer

Oscar Boutros Lahoud, MD, Dhakal Ajay, MD, Abhinav B Chandra, MD

Blood (2014) 124 (21): 5325.

https://doi.org/10.1182/blood.V124.21.5325.5325

Published: 2014

Journal Articles

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Muntasir Mamun Majumder, MSc, David Tamborero, PhD, Bhagwan Yadav, MSc, Mika Kontro, MD, Bjørn Gjertsen, MD PhD, Alun Parsons, MSc, Minna Suvela, BSc, Tero Aittokallio, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 3505.

https://doi.org/10.1182/blood.V124.21.3505.3505

Published: 2014

Journal Articles

Secondary ALL May be Independent of Prior Cytotoxic Therapy

Chezi Ganzel, MD, Sean M. Devlin, PhD, Dan Douer, MD, Eytan M. Stein, Jacob M. Rowe, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 3648.

https://doi.org/10.1182/blood.V124.21.3648.3648

Published: 2014

Journal Articles

Invasive neighbors

Ambra Paolini, Goretta Bonacorsi

Blood (2013) 122 (25): 4011.

https://doi.org/10.1182/blood-2013-08-520494

Published: 2013

Journal Articles

Poor Response To Imatinib In Patients With Secondary Chronic Myelogenous Leukemia

Jonathan Thompson, MD,, Kendra L. Sweet, MD, Ling Zhang, MD, Jasleen K Randhawa, MD, Christopher R. Chitambar, MD, Jessica K Altman, MD, Javier Pinilla, MD, PhD, Ehab Atallah, MD

Blood (2013) 122 (21): 5170.

https://doi.org/10.1182/blood.V122.21.5170.5170

Published: 2013

NARROW

Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)

Therapy Related Myeloid Neoplasms- Clinical, Pathologic and Genetic Characteristics - a Single Center Experience

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Therapy-Related Myeloid Neoplasms Are Not Always Dismal If They Have Better Cytogenetic Profile and Longer Latency Period from Preceding Anti-Cancer Treatment

Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs

Impact of Bioflavonoid Exposure on DNA Damage Response and of Non-Homologous End Joining (NHEJ) Pathway Repair Proteins in Stem Cells

Clinical and Molecular Characteristics of Therapy-Related Acute Lymphoblastic Leukemia

Philadelphia (Ph) Chromosome ( BCR-ABL1 fusion) As a Recurrent Genetic Abnormality Among Therapy-Related Acute Leukemia

Comparison of Two Rapid Predictive Methods for Therapeutic Targeting in Acute Myeloid Leukaemia Cells

Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis

Emerging Risks of AML/MDS and Other Myeloid Neoplasms Following Chemotherapy for First Primary Malignancy, 2000-2012

Concomitant Acute Promyelocytic Leukemia and Chronic Lymphocytic Leukemia: Molecularly Two Distinct Diseases

Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Dinaciclib, a CDK Inhibitor, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition

Early Occurrence of Therapy-Related Acute Myeloid Leukemia (t-AML) with Monocytic Differentiation with Trisomy 8 Cytogenetic Abnormality after Radioactive Iodine (RAI) Treatment for Papillary Thyroid Cancer

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Secondary ALL May be Independent of Prior Cytotoxic Therapy

Invasive neighbors

Poor Response To Imatinib In Patients With Secondary Chronic Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only